Ozempic has been linked to a rare but serious eye condition called NAION, which can cause sudden vision loss. Doctors are taking patient reports seriously as research finds higher rates of NAION in people taking Ozempic, especially those with diabetes or eye disease.

See If You Qualify for an Ozempic Lawsuit Get a Free Case Review

Ozempic and other GLP-1 drugs have been connected to a serious eye condition called NAION, which stands for non-arteritic anterior ischemic optic neuropathy. This condition occurs when the optic nerve does not receive enough blood, sometimes leading to sudden, painless vision loss in one eye.

A 2024 study in JAMA Ophthalmology, conducted by a team from Mass General, found that semaglutide use was linked to a higher risk of developing NAION.

People with diabetes, high blood pressure or other vascular risk factors may already be more likely to have optic nerve problems. The research also includes people using GLP-1 drugs for weight loss.

JAMA Ophthalmology Study Findings
  • Among patients with Type 2 diabetes (T2D), those receiving semaglutide exhibited a 4.28 times higher risk of NAION compared to users of non–GLP-1 diabetes medications.
  • Among overweight or obese patients, semaglutide users demonstrated a 7.64 times higher risk of NAION compared to those using non–GLP-1 weight-loss medications.
Source: JAMA Ophthalmology

If you notice vision changes after starting Ozempic, do not assume they are normal or temporary. It is important to get checked by a doctor immediately.

What Are the Symptoms of Ozempic-Related Vision Loss?

Symptoms of NAION may include:
  • Blurry, dark or worsening vision in part of your field of vision
  • Headache
  • Muscle pain when eating or chewing
  • Sudden, painless vision loss in one or both eyes
  • Swollen temple arteries
  • Vision loss upon waking
  • Weakened color vision

Symptom onset can happen quickly and may be permanent in some cases. Understanding the condition can alert you to sudden changes and allow you to seek medical attention earlier.

Sudden Vision Loss — What It Feels Like

Vision loss from NAION usually happens quickly and painlessly. You may notice blurred vision or worse vision in part of your field of view. This is usually in the lower half of the affected eye. It can also make colors look less vivid.

Most people first notice vision loss when they wake up. It may be after a full night’s sleep or even a short nap. In some cases, the vision loss develops more slowly over about two weeks.

NAION typically affects only one eye at a time. About 15% of people who get NAION in one eye will later develop it in their other eye as well. If you wake up and notice your vision has changed, it is important to take it seriously.

Temporary vs. Permanent Vision Changes

Some people taking Ozempic have temporary blurry vision because of changes in blood sugar, which is different from NAION. Vision loss from NAION is typically permanent, so it is important to know the difference.

If your vision changes suddenly, does not hurt, and does not return to normal, see an eye doctor as soon as you can.

When to Seek Care
  • A dark spot or missing area in your vision
  • Painless but persistent vision changes
  • Sudden vision loss in one eye
  • Vision changes that started after taking Ozempic
  • Washed-out, dull or dim vision

Does Ozempic Cause Blindness? What the Research Says

Some research suggests a link between Ozempic and NAION, but the overall risk appears to be low. Still, anyone who notices sudden changes in their vision should take it seriously.

Multiple research studies have found that people taking semaglutide were more likely to develop NAION compared to those using other medications.

In addition to the 2024 Mass General study that first suggested a link, a 2025 study in JAMA Ophthalmology found that patients had a 2.27-fold higher risk of NAION compared with those taking Jardiance (empagliflozin) when using a stricter NAION definition.

A 2026 report in JAMA also found that U.S. veterans with Type 2 diabetes who started Ozempic or other semaglutides had twice the risk of developing NAION compared to those who started another type of diabetes drug called SGLT2 (sodium-glucose co-transporter 2) initiators.

NAION is a concern because it can harm the optic nerve before you notice any symptoms, and the vision loss it causes is often permanent.

However, the FDA has not officially said that Ozempic causes blindness, but recent updates to prescribing information have brought more attention to vision risks. This makes it an important issue for both patients and doctors as research continues.

Did you or a loved one suffer from vision loss or severe gastroparesis after taking Ozempic?
Get a Free Case Review

Who Is Most at Risk for Vision Problems on Ozempic?

People with Type 2 Diabetes may face a higher risk of vision problems while taking Ozempic, especially if they already have eye disease linked to diabetes.

Researchers, writing in BMC Medicine in 2025, analyzed reported side effects from the FDA’s database to determine whether people taking Ozempic and other semaglutide medications had more vision problems than those taking similar drugs.

They identified several conditions that may make people taking Ozempic more likely to develop eye complications.

Conditions and Factors Linked to a Higher Risk of Vision Problems
  • Existing diabetic retinopathy or other eye disease
  • Type 2 diabetes
  • Diabetes lasting 10 years or longer
  • Age 60 or older
  • Rapid drops in blood sugar levels
  • A history of vision problems, specifically pre-existing retinopathy
  • Other diabetes-related health issues

The study found a possible connection between semaglutide and vision problems, but researchers said more studies are needed to prove whether the drug directly causes these eye conditions.

People with these risk factors should watch for any sudden or unusual changes in their vision. Your risk of NAION is higher in the first year on Ozempic, so you should have regular eye exams while taking a GLP-1 medication.

Ozempic Vision Loss Lawsuits — What You Should Know

People who developed vision problems while taking Ozempic, Wegovy or other GLP-1 drugs have filed lawsuits claiming the manufacturer failed to warn patients about the risk of NAION. Cases are still being accepted, and people who experienced sudden vision loss or NAION while on a GLP-1 drug may be eligible.

Some Ozempic lawsuits have been consolidated in a multidistrict litigation (MDL) in a federal court in Pennsylvania. MDLs allow several similar lawsuits to be combined into a single litigation to move more efficiently through the legal process.

Others were combined in a multicounty litigation (MCL) in a New Jersey state court. MCLs function in much the same way as MDLs do in federal court.

Frequently Asked Questions About Ozempic and Vision Loss

Yes. Research has linked Ozempic and other GLP-1 drugs to NAION, a serious eye condition causing sudden, permanent vision loss in one eye. A Mass Eye and Ear study found that semaglutide users were more likely to develop NAION than those on other medications, and lawsuits have been filed over this risk.
Temporary blurry vision from blood sugar changes may improve after stopping the drug. However, NAION-related vision loss is typically permanent because optic nerve damage does not fully reverse. Sudden vision changes should be checked immediately.
It is often described as sudden, painless vision loss in one eye, sometimes noticed upon waking. People may also see a dark spot, washed-out colors, or a missing part of their visual field. If you experience these symptoms, you should seek medical attention immediately.
Diabetic retinopathy differs from NAION and may improve as blood sugar stabilizes. Ozempic is not believed to directly damage the retina. Studies suggest some people may experience a temporary worsening of diabetic retinopathy when blood sugar drops too quickly, especially during the first year of treatment. The risk is highest in people with existing retinopathy and poorly controlled diabetes. Long-term blood sugar control with semaglutide may help slow future retinopathy progression.
See an ophthalmologist immediately, inform your prescribing doctor and document when the vision change began. If NAION is confirmed, you may have legal options. People who developed this condition after taking Ozempic or another GLP-1 drug have filed lawsuits.

Please seek the advice of a qualified professional before making decisions about your health or finances.

Terry Turner
Written By Terry Turner Senior Writer

Terry Turner has been writing articles and producing news broadcasts for more than 30 years. An Emmy-winning journalist, he has reported on consumer policy issues before Congress, the Consumer Product Safety Commission, the Food and Drug Administration and other federal agencies.

Renée Deveney
Edited By Renée Deveney Senior Content Editor

Consumernotice.org adheres to the highest ethical standards for content production and references only credible sources of information, including government reports, interviews with experts, highly regarded nonprofit organizations, peer-reviewed journals, court records and academic organizations. You can learn more about our dedication to relevance, accuracy and transparency by reading our editorial policy.

  1. Mount Sinai Health System. (2025, September 22). How the New Weight-Loss Drugs Might Affect Your Vision. Retrieved from https://health.mountsinai.org/blog/how-the-new-weight-loss-drugs-might-affect-your-vision/
  2. Massey, M. et al. (2025, April 7). Increased Vision Impairment Reports Linked to Semaglutide: Analysis of FDA Adverse Event Data. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC11974072/
  3. Heberer, K., et al. (2026, February 12). New-Onset Nonarteritic Anterior Ischemic Optic Neuropathy and Initiators of Semaglutide in US Veterans With Type 2 Diabetes. Retrieved from https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2844873
  4. Cai, C.X., et al. (2025, February 20). Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy. Retrieved from https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2830475
  5. Hathaway, J.T., et al. (2024, July 3). Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. Retrieved from https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2820255

More On This Topic

Related Posts